#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Epidemiology, Microbiology, Immunology / 2025 - 1

Drug injecting and other risk behaviours among potential clients of the mobile drug consumption room in Brno, Czechia

Czech version

Authors: V. Mravčík 1,2;  B. Janíková 1,2;  D. Thanki 1;  D. Nováková 2
Authors‘ workplace: Společnost Podané ruce, Brno 1;  Klinika adiktologie, 1. lékařská fakulta, UK a VFN v Praze 2
Published in: Epidemiol. Mikrobiol. Imunol. 74, 2025, č. 1, s. 53-64
Category: Original Papers
doi: https://doi.org/10.61568/emi/11-6445/20250128/139687

Overview

Background: Injecting drug use is associated with a high disease burden, particularly due to the high risk of blood-borne infections such as viral hepatitis C (HCV) and human immunodeficiency virus (HIV) infection. Interventions recommended for the prevention and control of infections associated with drug use include so-called drug consumption rooms (DCRs). A DCR is a professional addiction service where people who use drugs (PWUD) can consume the drug they bring under safer and hygienic conditions. In September 2023, the first DCR in the Czech Republic was opened in Brno as a mobile setting (MDCR) in a socially excluded location (SEL) with a high prevalence of heroin and other opioids injecting, especially in the local Roma community. Its launch involved mixed methods research aimed at needs analysis and service set-up. This paper presents an analysis of quantitative data focusing on risk behaviours and other characteristics of potential clients of the programme.

Material and methods: Two cross-sectional questionnaire surveys (n=131 and n=135) were conducted just before and after the launch of the programme among PWUD recruited through convenience sampling by collaborating services and peer workers in Brno. The analysis addressed the characteristics of clients in the SEL where the MDCR operates. Pairwise associations between the SEL affiliation and other variables were analysed using the chi-square test and t-test. For statistically significant predictors from the pairwise analysis, logistic regression analysis was performed, with adjustment for gender and age. Results are presented as adjusted odds ratios (AOR). Results: In both surveys, two thirds were male, mean age around 37 years (36.5 years in survey 1 and 37.5 years in survey 2). Most of them were people who injected drugs with a relatively high rate of risk behaviours. In survey 2, more people self-reported Roma ethnicity (50.7% versus 20.3%) and opioids as their primary drug (39.7% versus 27.5%). Respondents from survey 1 living in the SEL were more likely to have used heroin (AOR=8.2) and opioids (4.7) in the past year, to have injected drugs in an indoor public space in the past 30 days (3.6), to have witnessed an overdose (2.5), and to have been taken by emergency services (2.6) in the past 12 months. SEL respondents were more likely to have been clients of addiction services in the past year (2.8), especially opioid agonist treatment (4.6), but on the other hand, showed significantly more barriers to treatment. The survey after the MDCR launch confirmed higher rates of opioid use (2.9) and lower rates of methamphetamine use (0.3) and showed a higher prevalence of ever-diagnosed HCV (3.0) among SEL respondents. Prior to the opening of the MDCR, SEL respondents were in general less aware of the DCR (0.4) but reported greater willingness to use it after its launch (2.7).

Conclusion: The launch of the mobile DCR in Brno was justified due to the high prevalence of injecting drug use and the presence of associated risks, including injecting in public. The location of the DCR is appropriate as PWUDs in the SEL where it operates exhibit higher levels of risk behaviour and vulnerability. At the same time, they show a higher willingness to use the DCR. The set-up of DCR in Brno and its impacts on the health and social situation of clients and the community should be further monitored.

Keywords:

infectious disease – drug consumption room – drug injecting – risk behaviour – harm reduction

Sources
  1. Mravčík V, Florián Z, Nečas V, Štolfa J. Infekční a další somatická komorbidita problémových uživatelů drog – výsledky průřezové studie s lékařským vyšetřením. Epidemiologie, Mikrobiologie, Imunologie, 2016;1(65):56–62.
  2. Mravčík V, Chomynová P, Grohmannová K. Veřejnozdravotní význam užívání návykových látek. Hygiena, 2019;64 (1):21–26.
  3. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global health, 2017;5(12):e1192–e207.
  4. Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis., 2016;16(12):1385–1398.
  5. Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. The Journal of infectious diseases, 2014;209(8):1205–1211.
  6. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, 2018;113(3):545–563.
  7. ECDC, EMCDDA. Prevention and control of infectious diseases among people who inject drugs: 2023 update. Stockholm: ECDC; 2023 2011.
  8. WHO. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022.
  9. Hedrich D, Pirona A, Wiessing L. From margin to mainstream: The evolution of harm reduction responses to problem drug use in Europe. Drugs: education, prevention and policy, 2008;15(6):503– 517.
  10. Rhodes T, Hedrich D. Harm reduction and the mainstream. In: Rhodes T, Hedrich D, editors. Harm reduction: evidence, impacts and challenges Scientific Monograph Series No 10. Lisbon: European monitoring centre for drugs and drug addiction; 2010.
  11. Hunt N, Ashton M, Lenton S, Mitcheson L, Nelles B, Stimson G. A review of the evidence-base for harm reduction approaches to drug use Forward Thinking On Drugs 2003 [cited 2014 July 7]. Available at www: https://www.researchgate.net/publicati- on/242557610_A_review_of_the_evidence-base_for_harm_reduction_approaches_to_drug_use.
  12. EMCDDA. Prevence smrtelných předávkování. Zaostřeno, 2019;2019(1):1–8.
  13. Levengood TW, Yoon GH, Davoust MJ, Ogden SN, Marshall BDL, Cahill SR, et al. Supervised Injection Facilities as Harm Reduction: A Systematic Review. American journal of preventive medicine, 2021;61(5):738–749.
  14. Kennedy MC, Karamouzian M, Kerr T. Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. Current HIV/AIDS reports. 2017;14(5):161–183.
  15. Folch C, Lorente N, Majó X, Parés-Badell O, Roca X, Brugal T, et al. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. Int J Drug Policy, 2018;62:24–29.
  1. MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy, 2014;25(1):34–52.
  2. Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend, 2014;145:48–68.
  3. Myer AJ, Belisle L. Highs and Lows: An Interrupted Time-Series Evaluation of the Impact of North America’s Only Supervised Injection Facility on Crime. Journal of Drug Issues, 2017;48(1):36– 49.
  4. Wood E, Tyndall MW, Lai C, Montaner JSG, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Substance abuse treatment, prevention, and policy, 2006;1:13.
  5. Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy, 2015;26 Suppl 1:S5–11.
  6. Behrends CN, Paone D, Nolan ML, Tuazon E, Murphy SM, Kapadia SN, et al. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. J Subst Abuse Treat., 2019;106:79–88.
  7. Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction, 2016;111(3):475–489.
  8. Tran V, Reid SE, Roxburgh A, Day CA. Assessing Drug Consumption Rooms and Longer Term (5 Year) Impacts on Community and Clients. Risk Manag Healthc Policy, 2021;14:4639–4647.
  9. Hedrich D, Kerr T, Dubois-Arber F. Drug consumption facilities in Europe and beyond. In: Rhodes T, Hedrich D, editors. Harm reduction: evidence, impacts and challenges. EMCDDA Scientific Monograph Series. Lisbon: European monitoring centre for drugs and drug addiction; 2010. p. 305–331.
  10. EMCDDA, C-EHRN. Joint report by the EMCDDA and C-EHRN: Drug consumption rooms. Lisbon: European Monitoring Centre for Drugs and Drug Addiction and Correlation – European Harm Reduction Network, 2023.
  11. EMCDDA. Infographic. Location and number of drug consumption facilities throughout Europe Lisbon: European Union Drugs Agency; 2023 [cited 2024 July 4]. Available at www: https:// www.euda.europa.eu/media-library/infographic-location-and-number-drug-consumption-room-facilities-throughout-europe_en.
  12. ENDCR. Location and number of drug consumption rooms throughout Europe. Amsterdam: Correlation – European Harm Reduction Network, 2024.
  13. Ricciardelli R, Whitten C, Johnston M. “How are we gonna get them off the drugs if they’re allowed to stay on it?” correctional officer perspectives on Overdose prevention sites in prisons. Criminal Justice Studies, 2024;37(1):39–58.
  14. McKendy L, Biro SM, Miron M, Keown LA. Understanding overdose incidents in Canadian federal custody. International Journal of Drug Policy, 2021;92:103131.
  15. EMCDDA. Spotlight on Drug consumption rooms Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2022 [cited 2024 July 5]. Available at www: https://www.euda.euro- pa.eu/spotlights/drug-consumption-rooms_en.
  16. Zábranský T. Aplikační a uživatelské místnosti: přehled dostupných zkušeností a výzkumu [Application and User Rooms: an Overview of Available Experiences and Research]. Praha: Městská část Praha 1; 1999. p. 20.
  17. Mladá K, Pavlovská A, Novák P. Vybrané harm reduction služby v Berlíně. Adiktologie, 2010(4):252–258.
  18. Zábranský T. Aplikační místnosti, nebo šlehárny? Praha: Listy Prahy 1 a Neviditelný pes; 2001 [cited 2024 July 7]. Available at www: https://www.minarcik.cz/noviny/aplikacni.htm.
  19. Procházková L, Herzog A. Kauza o Václavák aneb případová studie monitorující aktivity směřující k řešení situace výskytu otevřené drogové scény na Václavském náměstí v Praze. 2010 2010. Report No.
  20. Janíková B. Aplikační místnosti – centra pro zdravotnicky supervidovanou aplikaci omamných a psychotropních látek. Zaostřeno na drogy, 2011;9(1):1–11.
  21. Remešová R. Zřizování a provozování aplikačních místností pro uživatele drog: přehled zahraničních zkušeností. Praha: Univerzita Karlova; 2017.
  22. Janouškovec V. Aplikační místnosti pro uživatele drog – analýza potřeb. Praha: Univerzita Karlova; 2013.
  23. Moravcová M. Ne/zavedení aplikačních místností v České republice. Praha: Univerzita Karlova; 2014.
  24. Společnost Podané ruce. Program aplikační místnosti v Brně a jeho východiska. Brno: Společnost Podané ruce, 2023.
  25. Mravčík V. Mobilní aplikační místnost v Brně – prezentace. Seminář o aplikační místnosti v Brně; 29. června 2023; Podaná kavárna, Brno: Společnost Podané ruce; 2023.
  26. Společnost Podané ruce. Společnost Podané ruce spouští v Brně první program bezpečnější aplikace a prevence předávkování v České republice. Brno: Společnost Podané ruce; 2023 [cited 2024 July 7]. Dostupné na www https://podaneruce.cz/spolecnost-podane-ruce-spousti-v-brne-prvni-program-bezpecnejsi-aplikace-a-prevence-predavkovani-v-ceske-republice/.
  27. Národní monitorovací středisko pro drogy a závislosti. Multiplikátor 2019: průzkum mezi klienty nízkoprahových programů. 2019.
  28. Janíková B, Mravčík V. Séroprevalence VHC u injekčních uživatelů drog v ČR v roce 2018. Praha: Úřad vlády ČR, 2019.
  29. AdRes Institut. RDS studie – seroprevalenční studie a odhad problémového užívání drog ve statutárním městě Brně. Závěrečná zpráva. Brno: Magistrát města Brna., 2019.
  30. Mravčík V, Mladá K, Drbohlavová B. Infectious and Other Somatic Comorbidity in People who Inject Drugs – Results of a Cross-sectional Survey. Adiktologie. 2018;18 (3–4):141–150.
  31. Mravčík V, Kožený J, Nečas V, Tišanská L. Bariéry léčby infekčních a dalších somatických onemocnění u uživatelů drog. Epidemiol Mikrobiol Imunol., 2020;62(2):73–80.
  32. EMCDDA. DRID Guidance Module: Example questionnaire for bio-behavioural surveys in people who inject drugs. Lisbon: European monitoring centre for drugs and drug addiction, 2013.
  33. EMCDDA. Treatment demand indicator. Standard protocol 3.0. Guidelines for reporting data on people entering drug treatment in European countries. Lisbon: European monitoring centre for drug and drug addiction 2012.
  34. Taylor H, Curado A, Tavares J, Oliveira M, Gautier D, Maria JS. Prospective client survey and participatory process ahead of opening a mobile drug consumption room in Lisbon. Harm Reduction Journal., 2019;16(1):49.
  35. Taylor H, Leite Â, Gautier D, Nunes P, Pires J, Curado A. Community perceptions surrounding Lisbon’s first mobile drug consumption room. Dialogues in Health, 2022;1:100031.
  36. Trayner KMA, Palmateer NE, Hutchinson SJ, Goldberg DJ, Shepherd SJ, Gunson RN, et al. High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs. Int J Drug Policy, 2021;90:102731.
  37. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction, 2010;105(5):844–859.
  38. Woods S. Drug Consumption Rooms in Europe – organisational overview. Researchgate. doi: 10.13140/RG.2.2.34829.15842.; 2014.
  39. Mravčík V. Dekriminalizace a chytrá regulace psychoaktivních látek – moderní alternativa prohibice [Decriminalisation and smart regulation of psychoactive substances: a modern alternative to prohibition]. Čas Lék čes, 2023;162(6):231–237.
  40. Malinowska-Sempruch K, Lohman D. From drug prohibition to regulation: a public health imperative. Lancet, 2022;400(10353):645–646.
  41. Tyndall M, Dodd Z. How Structural Violence, Prohibition, and Stigma Have Paralyzed North American Responses to Opioid Overdose. AMA J Ethics., 2020;22(1):E723–8.
  42. Malliori M, Galinaki S, Papakonstantinou AK. ODYSSEAS: supervised use of drugs versus bureaucracy in Greece. The lancet Psychiatry, 2015;2(2):e3.
  43. Skretting A. The Nordic countries and public drug-injection facilities. Drugs: Education, Prevention and Policy, 2006;13(1):5–16.
  44. Holland A, Harris M, Hickman M, Lewer D, Shorter GW, Horsley J, et al. Overdose prevention centres in the UK. The Lancet Public Health, 2022;7(3):e196–e7.
  45. Jelínek J. Trestní zákoník a trestní řád s poznámkami a judikaturou. Praha: Leges; 2014.
  1. Ščerba F. Trestní zákoník: komentář. Praha: C.H. Beck; 2020.
  2. Mravčík V, Janíková B, Černíková T. Koncept aplikační místnosti v podmínkách ČR. Praha: Úřad vlády ČR, Sekretariát Rady vlády pro koordinaci politiky v oblasti závislostí, 2022.
  3. Hedrich D. European report on drug consumption rooms. Lisbon: European monitoring centre for drugs and drug addiction; 2004.
  4. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253–63; discussion 67–68.

Úloha autorů

VM, BJ, DN navrhli a koordinovali výzkumný projekt, DN vkládala data, DN a DT prováděly statistickou analýzu dat. VM vytvořil koncept tohoto článku. Všichni autoři se podíleli na vzniku článku a schválili jeho konečnou verzi.

Poděkování

Tento článek byl podpořen nadací The Western-Eastern European Partnership Initiative on HIV, viral hepatitis and tuberculosis (WEEPI), projekt ID 201 a programem Cooperatio, vědní oblast HEAS, které podpořily výzkumný projekt. Úřad vlády ČR, Jihomoravský kraj a město Brno podpořily samotnou realizaci MAM. Společnost Gilead Sciences s.r.o. podpořila samotnou realizaci MAM a publikaci výsledků výzkumu prostřednictvím peněžního grantu. Zdroje podpory neměly žádný vliv na design, průběh ani výsledky výzkumu. Autoři dále děkují za spolupráci místním institucím a samosprávě, zejména městské části Brno – sever.

Do redakce došlo dne 2. 8. 2024.

Adresa pro korespondenci:
doc. MUDr. Viktor Mravčík, Ph.D.
Společnost Podané ruce o.p.s.
Hilleho 1842/5 602 00 Brno
e-mail: mravcik@podaneruce.cz

Labels
Hygiene and epidemiology Medical virology Clinical microbiology
COVID-19 in the practice of maternity hospitals of various degrees in the Czech Republic
Toxoplasmosis – seroprevalence and trend over 10 years
Whole genome sequencing (WGS) characterisation of Neisseria meningitidis from invasive meningococcal disease in the Czech Republic in 2018–2024 – analysis of the impact of the COVID-19 pandemic
Shigellosis: an update on the disease and analysis of human cases in the Czech Republic, 2018–2023
Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2
Autoimmune diseases of the central nervous system in childhood – diagnosis (MRI CNS), clinical course, and treatment
The first autochthonous case of diphyllobothriosis, caused by broad fish tapeworm (Dibothriocephalus latus), in the Czech Republic
Vzpomínka na RNDr. Marii Brůčkovou, CSc. (*9. 2. 1930 v Humpolci – †9. 1. 2025 v Praze)
Article was published in

Epidemiology, Microbiology, Immunology

Issue 1
2025 Issue 1
Download issue PDF
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#